Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective, gastro-intestinal, pain/analgesic, anti-diabetic, neuro/central nervous system, gynecology, respiratory, dermatology, and cardiac diseases. It also provides vitamins, minerals, and nutrients, as well as mouth wash, shampoos, pregnancy detection kits, and condoms. The company was incorporated in 1973 and is headquartered in Mumbai, India.

Revenue projections:

Revenue projections for ALKEM
Revenue projections for ALKEM

ALKEM's revenue projections indicate a decrease from the prior year, which may make investors hesitant. A revenue decline could harm the company's bottom line, prompting investors to be more careful, as lower earnings often signal potential issues with profitability and future performance.

Financial Ratios:

currentRatio 2.76100
forwardPE 25.29910
debtToEquity 11.10600
earningsGrowth 0.04200
revenueGrowth 0.07100
grossMargins 0.63252
operatingMargins 0.08868
trailingEps 180.87000
forwardEps 213.95000

ALKEM's current ratio of 2.761 highlights the company's ability to easily cover its short-term debt using its available cash and assets. This indicates a strong liquidity position, ensuring ALKEM is unlikely to face difficulties in meeting immediate financial obligations.
ALKEM's Forward PE is within a good range, showing that the stock price compares well to its earnings. This suggests it isn't overpriced and leaves room for growth, making the stock appealing to investors looking for value and growth opportunities.
ALKEM's low Debt-to-Equity ratio shows that the company isn't heavily reliant on debt for financing. This implies a conservative approach to leveraging, reducing financial risk and demonstrating a solid financial foundation, which can enhance investor confidence in the company's long-term stability.
ALKEM's forward EPS being higher than its trailing EPS indicates that the company is expected to achieve greater profitability this financial year. This suggests improving earnings and a stronger financial position compared to the previous year's performance.

Price projections:

Price projections for ALKEM
Price projections for ALKEM

The price of ALKEM has regularly been close to the lower end of projections, suggesting that it might be struggling to meet market expectations. This trend raises questions about the company's future performance.

Recommendation changes over time:

Recommendations trend for ALKEM
Recommendations trend for ALKEM


Analysts have shown a buy bias for Alkem Laboratories Limited, marking it as a favorable investment option. This could inspire investors to see Alkem Laboratories Limited as a strong place to park their money, given the positive outlook and growth potential associated with the stock in recent evaluations.